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a b s t r a c t
Aim: To assess interleukin 15 (IL-15) serum levels in patients with seropositive myasthenia
gravis (MG); searching for potential relationship between IL-15 levels and clinical features
such as gender, age at onset, clinical presentation or treatment received.
Background: IL-15 plays pivotal role in T-cell dependent autoimmunity. Increased IL-15
serum levels have been reported in several autoimmune diseases including MG patients
from Japan.
Patients and methods: Sera of 42 seropositive MG patients (66.7% women), mean age 50.6
 23.7 years) have been tested by ELISA for IL-15 levels.
Results: There were no statistically signiﬁcant differences between IL-15 serum levels in MG
patients in comparison with controls as well as between subgroups of MG patients (early vs.
late onset and thymoma MG). Mean/median IL-15 serum levels were similar in MG patients
treated with corticosteroids (CS) and CS naïve. Outliers (very high values) were seen only in
untreated generalized MG patients.
Conclusions: Serum interleukin 15 levels in patients with seropositive myasthenia gravis do
not correlate with disease severity.
© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnns1. Introduction
Myasthenia gravis (MG) is a neuromuscular disease caused in
80–95% of patients by a T-cell dependent autoantibody
response against receptor for acetylcholine at the postsynaptic* Corresponding author at: Department of Neurology, Medical Univers
E-mail address: akostera@wum.edu.pl (A. Kostera-Pruszczyk).
https://doi.org/10.1016/j.pjnns.2017.12.011
0028-3843/© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Nmuscle membrane (AChRAb). AChRAb in the neuromuscular
junction cause neuromuscular transmission disturbances
and, as a consequence, muscle weakness and fatigability.
AChRAb serum levels show no correlation with the severity of
MG course and no biological marker of MG severity was
identiﬁed so far [1]. Also factors active in triggering andity of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.
eurological Society.
Fig. 1 – IL-15 serum levels in patients untreated vs. treated
with corticosteroids (CS) within last 3 months. Patients
treated with CS tend to have lower IL-15 serum levels ( p ns).
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Studies in experimental MG (EAMG) suggested that myocytes
are not only passive participants or target of the immunologic
cascade, but are active during the course of the disease by
producing speciﬁc cytokines, including interleukin 15 (IL-15)
[2,3]. IL-15 stimulates interferon gamma (INF gamma) produc-
tion. INF gamma in turn was proved to enhance experimental
MG symptoms [2,4–6]. IL-15 not only induces T lymphocytes
proliferation, enhances NK cells cytotoxicity and leads to
increased production of their cytokines and chemokines, but
also facilitates survival of CD8+ memory T cells including self-
reactive memory T-cells [7].
Increased IL-15 serum levels have been reported in several
autoimmune diseases, including systemic lupus erythemato-
sus, inﬂammatory bowel disease, multiple sclerosis, rheuma-
toid arthritis, diabetes type 1 or celiac disease [7,8]. Increased
serum IL-15 levels were reported in Japanese MG patients not
treated with immunosuppressants or thymectomy [8]. It
prompted us to verify the hypothesis that IL-15 serum level
is increased in a group of Caucasian seropositive MG patients
and test its possible relationship with clinical features such as
gender, age of onset, clinical presentation or treatment
received.
2. Patients and methods
2.1. Subjects
42 patients with seropositive MG were enrolled in this study in
the period between 2011 and 2014 after informed consent.
Clinical diagnosis of MG was conﬁrmed by positive result of
repetitive nerve stimulation test or single-ﬁbre electromyog-
raphy (SFEMG) and elevated serum anti-AChR levels. 66.7% of
tested patients were women; age of onset ranged from 15 to 85
years (mean 50.6  23.7 years). By deﬁnition all subjects had
seropositive MG. 42.9% of patients were classiﬁed as early
onset MG (EOMG, <50 years), 45.2% as late onset MG (LOMG,
≥50 years); 11.9% had thymoma-MG (T-MG). The majority
(78.6%) of the subjects were never treated with corticosteroids
(CS) or other immunosuppresants. 19% of all patients under-
went thymectomy. In 14.3% of the patients autoimmune
thyroid disease coexisted with MG. The severity of symptoms
was assessed according to Myasthenia Gravis Foundation of
America (MGFA) clinical classiﬁcation scale. 88.1% of subjects
had generalized MG. Two patients (4.8%) were in complete
stable remission. Sera of 16 subjects with no history of MG or
other autoimmune diseases served as normal controls. All sera
were frozen and stored at 73 8C until analysis.
2.2. Methods
IL-15 serum levels were measured by ELISA (BioLegend IL-15
Pre-coated ELISA Kit, according to the manufacturer's instruc-
tion, by MD). The detection limit of ELISA Kit was 2 pg/ml.
2.3. Statistical analysis
Independent-Samples T test, after Levene's Test for Equality of
Variances and U Mann Whitney test, were used to comparerespectively means and ranges of IL-15 serum levels within
groups taken into comparison. Correlations between IL-15 and
AChRAb serum levels and clinical and laboratory features were
studied using Pearson's and Spearman's tests, as appropriate.
Statistical signiﬁcance was deﬁned at p < 0.05.
3. Results
There was no signiﬁcant difference between serum Il-15 levels
in patients with MG as compared to controls (9.87  9.37
(median 7.38; Q1 = 4.51, Q3 = 10.28) vs. 8.69  3.61 pg/ml
(median 8.69; Q1 = 5.13, Q3 = 11.38), respectively; p = 0.449).
There was also no signiﬁcant difference between women and
men (9.29  7.79 (median 7.38; Q1 = 4.62, Q3 = 9.43) vs. 11.21
 12.64 pg/ml (median 6.81; Q1 = 4.28, Q3 = 11.31); p = 0.560).
Also the patients treated with corticosteroids within the last 3
months did not have lower Il-15 serum levels than patients
who have received prednisone recently (7.67  4.17 (median
8.02; Q1 = 4.04, Q3 = 11.31) vs. 10.19  10.05 pg/ml (median 7.05;
Q1 = 4.52, Q3 = 10.35), respectively; p = 0.941); there was also no
differences in IL-15 levels in patients treated with corticoste-
roids in the past vs. untreated (Fig. 1).
Patients with generalized MG had similar mean serum Il-
15 levels as patents with ocular MG only (9.92  9.85 (median
6.67; Q1 = 4.48, Q3 = 10.52) vs. 8.45  4.45 (median 8.97;
Q1 = 4.72, Q3 = 11.92); p = 0.641) (Fig. 2). Patients with EOMG
tended to have lower IL-15 serum levels from LOMG (8.53
 5.41 (median 6.62; Q1 = 4.58, Q3 = 10.89) vs. 11.65  12.87
(median 8.07; Q1 = 4.33, Q3 = 11.66); p = 0.380) (Fig. 3). There
were similar serum IL-15 levels in T-MG in comparison with
other MG groups (9.25  3.46 (median 8.59; Q1 = 6.17,
Q3 = 13.00) vs. 9.71  9.66; p = 0.936 (median 8.07; Q1 = 4.33,
Q3 = 11.66), respectively). We have not found signiﬁcant
differences between patients with or without autoimmune
thyroid disease (respectively 8.61  2.96 (median 7.05;
Q1 = 4.47, Q3 = 10.05) vs. 9.86  10.03; (median 6.72;
Q1 = 4.47, Q3 = 10.75) p = 0.283).
One patient had IL15 level below detection limit.
Fig. 2 – Serum IL-15 levels in ocular-MG vs. generalized-MG
patients. There are no differences in IL-15 serum levels
between groups ( p ns).
Fig. 3 – IL-15 serum levels within different types of MG.
Patients with early onset MG (EOMG) and thymoma-MG (T-
MG) tend to have lower serum IL-15 levels in comparison
with late onset MG (LOMG) ( p ns).
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In this study we have assessed IL-15 serum levels in patients
with seropositive MG and searched for potential relationship
between IL-15 levels and clinical features of the disease such
as gender, age at onset, clinical presentation or treatment
received. Although we have not found any statistically
signiﬁcant differences neither between MG patients and HC,
nor among different categories of MG patients, the IL15 results
in our study group were comparable to those reported before
[8,9]. The main difference between our cohort and the MG
patients reported by Uzawa were their treatment status. All of
Uzawa et al. patients were treatment-naive while 19% of ourshad history of immunosuppressive treatment. We have not
found any signiﬁcant differences among groups of MG
patients, nor between CS-treated and CS-naïve in mean IL-
15 serum level in patients treated with CS within last 3
months. All of the patients with highest IL15 values had
generalized MG and were not treated with CS.
Ocular MG patients tended to have slightly lower mean IL-
15 serum levels, although the difference was not statistically
signiﬁcant. This observation is consistent with Uzawa et al.
study where only generalized MG patients had statistically
signiﬁcant higher IL-15 serum levels in comparison with HC
and no such difference was noted for ocular MG patients.
Our series is the third study addressing IL-15 serum levels in
MG patients, although numerous studies on the potential IL-15
role in the pathogenesis and course of MG were conducted so far.
They led to the concept of immunological pathway, where
AChRAb lead to the activation of myocytes and increase of the
IL-4R on their surface; activated myocytes increase IL-15
production that enhances INF-gamma production and in
consequence escalates MHC II and ICAM 1 expression leading
to worsening MG symptoms [1–6]. IL-15 plays important role in
facilitating survival of CD8+ memory T cells including self-
reactive memory T-cells [7]. It has been proven that depletion of
CD8+ cells suppresses the development of experimental MG
[10,11]. Beneﬁcial effects of the decrease of IL-15 serum levels
has been also already observed in other autoimmune diseases
such as rheumatoid arthritis (RA) [12]. The beneﬁts resulting
from IL-15 activity blocking have been also observed in
experimental psoriasis model in mice [13]. Currently several
clinical trials using monoclonal antibodies targeting the cyto-
kine receptor subunit IL-2/IL-15Rb for IL-15 (CD122) and blocking
IL-15 transpresentation in autoimmune diseases are in progress.
Promising ﬁndings resulted from using these substances in the
study on transgenic mice with experimental celiac disease
[7,14]. The role of IL15 in MG patients requires further studies.
We conclude that although we did not demonstrate
relationship between IL15 serum levels and MG severity or
MG type in a studied cohort.
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